Prostate Cancer

One-Year Functional Satisfaction and Quality of Life Outcomes of Patients With a History of Radiotherapy With Artificial Urinary Sphincters. June 4, 2026

Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management. June 4, 2026

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer. June 4, 2026

Associations Between Medicaid Insurance, Facility Medicaid Share, and Guideline-Concordant Prostate Cancer Care - Beyond the Abstract June 3, 2026

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States. June 3, 2026

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. June 3, 2026

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study. June 3, 2026

Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer. June 2, 2026

Phase I design for partially ordered groups with late-onset toxicity. June 2, 2026

Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study. June 2, 2026

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer. June 4, 2026

Comparative functional, perioperative and oncological outcomes of robot-assisted and open radical prostatectomy: a systematic review and meta-analysis. June 4, 2026

USP2 is an androgen-repressed survival factor that stabilises oncoproteins to facilitate therapy resistance in prostate cancer. June 4, 2026

Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. June 3, 2026

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. June 3, 2026

Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study. June 3, 2026

Comparison of platinum and gold fiducial markers for prostate radiotherapy: a phantom study. June 2, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. June 2, 2026

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial. June 2, 2026

Perioperative Apalutamide in High-Risk Localized Prostate Cancer. June 2, 2026

Page 1 of 1634